Good signs ...., page-424

Optiscan's CLE Technology Takes Center Stage at IAOP President's Prize Lecture!

We are thrilled to announce that Dr. Camile Farah, CEO and Managing Director of Optiscan Imaging Ltd, will be presenting at the prestigious IAOP President’s Prize lecture.

His talk, "Oral Potentially Malignant Disorders - The Intersection of Molecular Genomics and Optical Imaging - A Paradigm Shift in Diagnosis and Management," will highlight the transformative impact of Optiscan’s confocal laser endomicroscopy (CLE) technology.

Key benefits of Optiscan’s CLE technology:
- Non-invasive, real-time optical biopsies
- Instantaneous, high-resolution imaging of oral tissues
- Accurate differentiation between dysplastic and non-dysplastic pathology

Our recent study showcased impressive results:
- Diagnostic Accuracy: 88.9%
- Sensitivity: 86.8%
- Specificity: 92%
- Positive Predictive Value (PPV): 94.3%
- Negative Predictive Value (NPV): 82.1%
- Carcinoma Detection: 100% accuracy

Join us to see how Optiscan’s innovative technology is changing the future of oral cancer diagnosis and management, enhancing early detection, and improving patient outcomes.